Cargando…

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment

To assess the methodological quality of cost-effectiveness analyses (CEA) of nivolumab in combination with ipilimumab, we conducted a systematic literature review in the first-line treatment of patients with recurrent or metastatic non-small cell lung cancer (NSCLC), whose tumors express programmed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaim, Remziye, Redekop, W. Ken, Uyl-de Groot, Carin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Health Services
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012633/ https://www.ncbi.nlm.nih.gov/pubmed/36926505 http://dx.doi.org/10.3389/frhs.2023.1034256

Ejemplares similares

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
por: Hao, Xuezhi, et al.
Publicado: (2021)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
por: Wan, Xiaomin, et al.
Publicado: (2021)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer
por: Courtney, P. Travis, et al.
Publicado: (2021)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
por: Çakar, Esra, et al.
Publicado: (2023)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
por: Sheng, Iris Y, et al.
Publicado: (2020)

Editorial: Advancements and challenges in cost and resource allocation: 2022
por: Hafidz, Firdaus, et al.
Publicado: (2023)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u2g95hikivbv5pij4bku0eped6